Get The Daily Rip

Stocktwits Top 25 – Week 30 📈

Welcome to the Stocktwits Top 25 Newsletter for Week 30 of 2022!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. 

Here are the Stocktwits Top 25 Lists for Week 30:

S&P 500

ST Top 25 S&P 500

The S&P 500 Top 25 list (+11.11%) significantly outperformed the S&P 500 index (+4.26%). 

There were six major changes to the list this week.

Enphase Energy (+34.34%), APA Corp. (+14.69%), SolarEdge Technologies (+24.64%), Pioneer Natural Resources (+12.94%), Sempra Energy (+7.49%), and T-Mobile US (+7.99%) joined the list.

They replaced Quanta Services (+4.26%), Eli Lilly (+0.29%), Bristol-Myers Squibb (+1.14%), Activision Blizzard (+0.91%), Dollar Tree (-3.87%), and Merck (-0.85%).

Energy and solar stocks rallied this week, while consumer staples and health care lagged.

Check out how the momentum meter has performed vs. the S&P 500 index this year:


The Large-Cap Nasdaq 100

The Nasdaq 100 Top 25 list (+4.86%) essentially matched the Nasdaq 100 index (+4.45%).

There were four major changes to the list this week.

Cadence Design Systems (+10.95%), Cintas Corp. (+7.25%), Automatic Data Processing (+9.43%), and Fiserv (+5.82%) joined the list.

They replaced Netease (-2.18%), Palo Alto Networks (-2.36%), Baidu (-2.46%), and Pinduoduo (-9.87%).

Chinese internet stocks Baidu and Pinduoduo are not participating in the U.S. tech stock rebound.


The Growth-Centric Russell 2000

The Russell 2000 Top 25 list (+13.31%) significantly outperformed the Russell 2000 index (+4.34%).

There were four major changes to the list this week.

Talos Energy (+25.33%), Helmerich & Payne (+17.51%), Patterson UTI Energy (+24.16%), and Kosmos Energy (+18.95%) joined the list.

They replaced Eiger Biopharma (+2.96%), Amphastar Pharma (+3.98%), Tenneco (+0.11%), and Meridian Bioscience (-2.91%).

Energy was the clear standout this week, with several biotech names continuing their run. This list continues to host big winners and losers every week.



The Top 25 lists’ Top Dawg was SIGA Technologies, which rallied 41.37%.

The biotech company was the top dawg back in week 20 as monkeypox began to spread in Europe, and one of the company’s drugs, TPOXX, could be used to treat it.

Last week, the World Health Organization (WHO) declared the virus a global health emergency, and the U.S. is expected to make a similar declaration at the national level soon. In the meantime, some states and cities like New York and San Francisco have declared it an emergency.

And for SIGA and other companies with treatment options for the virus, more infections equal more potential profits.

This week’s big news was the U.S. Food and Drug Administration (FDA) providing updated guidance on its response to the monkeypox outbreak.

Within it, it had this to say about therapeutic treatment of the virus.

“There is no FDA-approved or authorized medicine for the treatment of monkeypox disease; however, TPOXX (tecovirimat), an antiviral medication, is being made available through the CDC under an FDA authority called Expanded Access or “compassionate use.”

While that may seem like a positive development, the next paragraph likely dampened some of the market’s enthusiasm.

“There are currently no human data demonstrating the efficacy of TPOXX for the treatment of monkeypox, or the safety and pharmacokinetic profile (which helps us understand what the human body does to a drug). Although expanded access program is available, conducting randomized, controlled trials to assess TPOXX’s safety and efficacy in humans with monkeypox infections is essential.”

SIGA shares continue to be highly volatile as the situation develops but still managed to claim this week’s top spot despite Friday’s selloff.

$SIGA is up 125.89% YTD.

See Y’all Next Week 🤙